Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement April 21, 2026
Orphan Drug Designation Application Submitted to US FDA for SkinJect® for treating basal cell carcinoma (BCC) in patients with Gorlin Syndrome April 21, 2026
Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma April 15, 2026
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program March 10, 2026
Ph 2 SKNJCT-003 Trial Reported 73% Clinical Clearance and 40% Histological Clearance (CR) with D-MNA in BCC March 10, 2026
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall DCR in Melanoma Announced February 9, 2026
Multiple Sites Activated for Ph 1b/2 Trial of AMXT 1501 and DFMO in Patients with solid tumors including Breast Cancer and Melanoma February 9, 2026
Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers January 25, 2026
5-Year Data for Intismeran Autogene + KEYTRUDA combo Demonstrated Sustained RFS Improvement in High-Risk Stage III/IV Melanoma Following Complete Resection January 25, 2026
Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial of bexmarilimab + zimberelimab December 30, 2025
Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma December 15, 2025
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced CSCC December 9, 2025
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced CSCC December 2, 2025
First Patient Dosed in SANTANA-225 Ph 1/2 Trial of 225Ac-SSO110 in Patients with ES-SCLC or MCC November 18, 2025
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 in “NEO-CYT” trial in High-Risk, Surgically Resectable Neoadjuvant Stage III Melanoma November 10, 2025
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of CSCC with a High Risk of Recurrence After Surgery and Radiation October 21, 2025
TransCode Therapeutics to acquire Polynoma and use $25M funds by CK Life Sciences to advance TTX-MC138 into Ph 2 trial October 16, 2025
Libtayo® (cemiplimab-rwlc) Approved in US for Adjuvant Treatment of CSCC with a High Risk of Recurrence After Surgery and Radiation October 15, 2025
FDA Fast Track Designation to WTX-124 for locally advanced or metastatic cutaneous melanoma after SOC immunotherapy October 15, 2025
